Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave

The maker of the high-selling tirzepatide injectable medication sold under the "We are an innovative company with an innovative product, and we price based on the value delivered to patients, physicians, and the healthcare system," Tucker said in an interview. "Tirzepatide is priced for the value it provides. Generic markets are separate...There is room for both segments.""Also, we offer both prefilled monthly pen and vial options, which gives patients some flexibility," said Tucker.His comments come ahead ...